Szlezinger, Katarzyna
Pogoda, Katarzyna
Jagiełło-Gruszfeld, Agnieszka
Kłosowska, Danuta
Górski, Andrzej
Borysowski, Jan
Article History
Received: 22 February 2023
Accepted: 16 June 2023
First Online: 3 July 2023
Declarations
:
: Not applicable.
: Not applicable.
: K.P.: honoraria: AstraZeneca, Gilead, Eli Lilly, MSD, Roche, Pfizer, Egis, Teva, Novartis; fee conference support: Gilead, Astra Zeneca, Eli Lilly; contracted research: AstraZeneca, Roche, Eli Lilly, Novartis, GlaxoSmithKline, Pfizer. A.J.-G.: Advisory Board: Eli Lilly, AstraZeneca, Gilead, MSD; Speaker: Roche, Pfizer, Amgen, Novartis, Teva, Lilly, Angelini, Gilead; Clinical trials (co-investigator): Roche, AstraZeneca, Lilly, Novartis, MSD, Pfizer; Conference grants: AstraZeneca, Pfizer. All remaining authors declare that they have no competing interests.